Valo Health Acquires Courier Therapeutics

Valo Health has acquired Courier Therapeutics, a biotechnology company founded at Washington University in St. Louis that developed a protein therapeutics platform and the tumor-targeting candidate OPL-0101. The acquisition extends Valo’s Opal Computational Platform into protein therapeutics and is expected to broaden Valo’s modalities and capabilities across oncology and other therapeutic areas; the deal includes an upfront payment and milestone-based consideration.